Company reports: tau shot lowered spinal-fluid tau; skin clock fell with topical
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description reports company data: an under-the-skin tau drug cut spinal-fluid tau by a mean 73% in healthy volunteers, and a topical was linked to a mean 2.1-year lower skin epigenetic age in eczema. Neither shows memory, disease or lifespan benefits. [1]
The maker says ARO-MAPT, injected under the skin, lowered spinal-fluid tau by a mean 73% at day 105 in the top-dose cohort of healthy volunteers, and by up to 85% in one person. [1]
In a small Phase 1b study in people with atopic dermatitis, measured skin epigenetic age was a mean 2.1 years lower across 11 paired samples after four weeks. [1]
Deep Origin says its AI virtual screening delivered multiple structurally distinct hits against a new BioAge target in under three months; these are early lab hits, years from patients. [1]
Tau shot in healthy volunteers
According to the description, the maker Arrowhead says its investigational RNAi drug ARO-MAPT, injected under the skin, lowered tau in spinal fluid by a mean 73% at day 105 in the top-dose cohort of healthy volunteers, and by up to 85% in one person. Day 105 is about 90 days after the final dose, which the company says supports possible dosing about every three months. This is interim company data and a biomarker measured in healthy people. [1]
Skin clock in eczema trial
The description says Rubedo Life Sciences tested RLS-1496, a topical meant to clear senescent cells, in a small Phase 1b study in people with atopic dermatitis (eczema). After four weeks, measured skin epigenetic age was a mean 2.1 years lower across 11 paired samples (p=0.032), and one best responder was down 11.7 years at day 63. This is company data from one aging clock. A clock reading estimates biological age; it is not proof of visibly younger skin or a longer life. [1]
AI screening hits and open questions
The description says Deep Origin's AI virtual screening delivered multiple structurally distinct hits against a new BioAge target, chosen from human aging data, in under three months. BioAge validated them in its own lab and is moving the target into hit-to-lead work. These are early lab hits, years away from any patient. For the tau drug, effects on tau tangles, memory and disease progression have not been tested yet; a Part 2 is enrolling people with early Alzheimer's disease. [1]
Context & limits
Based only on the video description; the video and transcript were not reviewed. All results are company-reported. The tau figure is interim data on a biomarker in healthy volunteers, with no tested effects on tangles, memory or disease progression. The skin-clock result comes from one aging clock in a small eczema study and does not show visibly younger skin or longer life. The AI hits are early laboratory findings.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
lowered tau in spinal fluid by a
a mean 2.1 years lower across 11
multiple structurally distinct hits against a new
About this video
Creator description · original textText language: English
Philipp Karner · 3 min · Source published: 2026-10-18
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.